StockData
Avalo Therapeutics, Inc. logo

Avalo Therapeutics, Inc. (AVTX) stock

AVTXNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 5, 2026Score 8/30
$7.13−0.24 (-3.26%)

Close on Nov 17, 2026Market cap $382.38MP/E –Yield –

Avalo Therapeutics price to book ratio

The price-to-book ratio is market cap divided by shareholders' equity.

Avalo Therapeutics's price to book ratio was 1.0× on Nov 11, 2026, against 3.7× a year earlier. Over the last 5 years it ranged from 0.3× to 13.8×, with a median of 3.6×.

Price to Book Ratio at the end of each year

PeriodPeriod endValueChange (pts)
2026Nov 11, 20261.0×−2.5
2025Dec 31, 20253.5×+0.1
2024Dec 31, 20243.4×+2.9
2023Dec 29, 20230.5×−4.8
2022Jul 29, 20225.3×+0.6
2021Dec 31, 20214.7×−0.4
2020Dec 31, 20205.1×−7.9
2019Dec 31, 201913.0×+6.3
2018Dec 31, 20186.7×+3.0
2017Dec 29, 20173.8×−9.8
2016Dec 30, 201613.6×–

More Avalo Therapeutics figures

See a number that looks wrong?